Long-term CV outcome studies have shown that PCSK9 inhibitors reduce CV event rates similarly in individuals with and without T2DM and prior CV disease or recent acute coronary syndrome [15, 16]. The gene discussed is PCSK9; the disease is acute coronary syndrome.